Filing Details

Accession Number:
0001209191-19-044032
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-01 16:31:54
Reporting Period:
2019-07-30
Accepted Time:
2019-08-01 16:31:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1685071 Dova Pharmaceuticals Inc. DOVA Pharmaceutical Preparations (2834) 813858961
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1709417 Kevin Laliberte C/O Dova Pharmaceuticals, Inc.
240 Leigh Farm Road, Suite 245
Durham NC 27707
Sr. Vp, Product Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-07-31 1,389 $15.97 11,557 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Acquisiton 2019-07-30 10,000 $0.00 10,000 $16.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,000 2029-07-30 No 4 A Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.60 to $16.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  3. One-fourth (1/4th) of the shares vest July 30, 2020, and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter, subject to the Reporting Persons continuous service as of each such date.